WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognized Acromegaly Awareness Day, the patient community and the tremendous work being done to enhance patients’ quality of life.
“Through years of partnering with the patient community, we have forged a strong bond with many of those who struggle with this rare and debilitating disease,” said Mark Fitzpatrick, president and CEO of Chiasma. “On Acromegaly Awareness Day, we take this opportunity to publicly honor people living with acromegaly and their families. We are proud to work on their behalf toward our goal of advancing a potential new oral treatment option for adult patients with acromegaly, and we look forward to continuing this important mission.”
“The acromegaly community has been encouraged by the commitment of Chiasma to developing octreotide capsules as a potential oral treatment option for people living with this rare disease,” said Jill Sisco, president of the Acromegaly Community. “In honor of Acromegaly Awareness Day, we wish to thank all those who continue to explore future treatment options to potentially improve our daily quality of life.”
Chiasma recently announced the randomization of the first patient in its new Phase 3 trial referred to as “CHIASMA OPTIMAL” (Octreotide capsules vs. Placebo Treatment In MultinationAL centers). In addition, Chiasma continues to conduct its international Phase 3 MPOWERED (Maintenance of Acromegaly Patients with Octreotide Capsules Compared With Injections – Evaluation of REsponse Durability) clinical trial of octreotide capsules in acromegaly that it initiated in March 2016 to support potential regulatory approval in Europe. Octreotide capsules are an investigational new oral drug proposed for the maintenance therapy of adult patients with acromegaly. Acromegaly is most commonly caused by a benign tumor of the pituitary gland that produces excess growth hormone (GH), ultimately leading to significant health problems and early death if untreated. GH regulates multiple metabolic processes and stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver, which stimulates the growth of bones and other tissues. If approved, octreotide capsules may be the first oral somatostatin analog treatment option available for acromegaly patients, where the current standard of care is somatostatin analog injections.
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The company recently initiated a new Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named Mycapssa®, for the maintenance therapy of adult patients with acromegaly following agreement with the FDA on the design of the trial. Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel. Mycapssa and TPE are registered trademarks of Chiasma.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s commitment to develop new treatment options for patients with rare and serious chronic diseases, specifically acromegaly, the company’s efforts to potentially obtain regulatory approval in the United States by conducting the new Phase 3 CHIASMA OPTIMAL clinical trial under a Special Protocol Assessment and the company’s efforts to potentially obtain regulatory approval in Europe by conducting the Phase 3 MPOWERED clinical trial. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the Securities and Exchange Commission (SEC) on August 10, 2017, and in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this information unless required by law.
Sharon Merrill Associates